Dihydrofolate Reductase antibody (AA 1-187)

Catalog No. ABIN5540915

This Mouse Monoclonal antibody specifically detects Dihydrofolate Reductase in WB and EIA. It exhibits reactivity toward Human.

Quick Overview for Dihydrofolate Reductase antibody (AA 1-187) (ABIN5540915)

Target: Dihydrofolate Reductase (DHFR)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Dihydrofolate Reductase antibody is un-conjugated

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Clone: AT5B2

Product Details anti-Dihydrofolate Reductase Antibody

Binding Specificity: AA 1-187

Purification: Protein-A affinity chromatography

Immunogen: Recombinant human DHFR (1-187aa) purified from E. coli.

Isotype: IgG1

Application Details

Application Notes: The antibody has been tested by ELISA, Western blot analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Liquid. In Phosphate-Buffered Saline ( pH 7.4) with 0.02 % Sodium Azide, 10 % Glycerol.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch.

Expiry Date: 12 months

Target Details for Dihydrofolate Reductase

Target: Dihydrofolate Reductase (DHFR)

Alternative Name: dhfr,dhfrp1

Background: Dihydrofolate reductase (DHFR) catalyzes the DPH-dependent reduction of dihydrofolate to tetrahydrofolate, and is a crucial enzyme for the synthesis of purines, pyrimidines and some amino acids. Inhibition of the activity of this enzyme leads to arrest of D synthesis and cell death. Gene expression of methotrexate (MTX)-resistant variants of DHFR in normal hematopoietic cells is a potential strategy to permit administration of larger doses of MTX by alleviating drug toxicity in normal cells and tissues that are drug sensitive.

UniProt: P00374

Pathways: Mitotic G1-G1/S Phases